Retinopathy in juvenile diabetes: A 10-year (1990-2000) review

Pediatric Diabetes

Volumn 2, Issue 2, 2001, Pages 83-93

  Giusti, Cristiano ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b NONE   (Italy)

Author keywords

Adolescence; Childhood; Diabetic retinopathy; Retina; Type 1 diabetes

Indexed keywords

ACETAZOLAMIDE; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ANTIHISTAMINIC AGENT; DEFIBROTIDE; GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C;

ADOLESCENT; BLINDNESS; CHILD; DIABETIC RETINOPATHY; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; INDUSTRIALIZATION; JUVENILE DIABETES MELLITUS; LASER SURGERY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOCIAL ASPECT; SYMPTOM; TIME; VISUAL IMPAIRMENT; VITRECTOMY; WESTERN HEMISPHERE;

EID: 0034967644     PISSN: 1399543X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5448.2001.002002083.x     Document Type: Review

References (138)

1. The 14-year incidence of visual loss in a diabetic population
2. Prevalence and correlations of early microvascular complications in young type 1 diabetic patients: Role of puberty
3. Diabetic retinopathy screening is a requirement. Don't wait until vision becomes impaired
4. Monitoring for retinopathy in children and adolescents with type 1 diabetes
5. Ocular complications in young adults with insulin-dependent diabetes mellitus since childhood
6. Screening for diabetic retinopathy in childhood: Do the eyes have it?
7. The relationship of puberty to diabetic retinopathy
8. Prevalence of diabetic retinopathy in children and adolescents with IDDM. A population-based multicentre study
9. Diabetic retinopathy in pediatric patients with type 1 diabetes: Effect of diabetes duration, prepubertal and pubertal onset of diabetes and metabolic control
10. Diabetes complication screening in 937 children and adolescents
11. Prevalence of retinopathy in diabetic thalassemic patients
12. Reduced retinal vascularization in children with growth hormone deficiency
13. Biomedical and psychiatric risk factors for retinopathy among children with IDDM
14. Prevention of microvascular complications in diabetic children and adolescents
15. The progression of retinopathy over 2 years: The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study
16. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complication Trial
17. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVI. The relationship of C-peptide to the incidence and progression of diabetic retinopathy
18. The 10-year incidence of renal insufficiency in people with type 1 diabetes
19. A six-year follow-up study of smoking habits and microvascular complications in young adults with type 1 diabetes
20. Ocular factors in the incidence and progression of diabetic retinopathy
21. Incidence of diabetic retinopathy in myopic eye
22. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications
23. Serum total renin, an independent marker of the activity and severity of retinopathy in patients with IDDM
24. Fetal growth is not associated with early onset of severe retinopathy in type 1 diabetes mellitus
25. Diabetic retinopathy in pregnancy: Effects on the natural course
26. Does the severity of diabetic retinopathy predict pregnancy outcome?
27. Diabetic retinopathy in pregnancy during tight metabolic control
28. Is menarche associated with diabetic retinopathy?
29. Increased testosterone in type 1 diabetic subjects with severe retinopathy
30. Sex hormones and the incidence of severe retinopathy in male subjects with type 1 diabetes
31. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus
32. Development of proliferative diabetic retinopathy in African-Americans and whites with type 1 diabetes
33. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort
34. Metabolic control and prevalence of microvascular complications in young Danish patients with type 1 diabetes mellitus. Danish Study Group of Diabetes in Childhood
35. A 3-19-year follow up study on diabetic retinopathy in patients diagnosed in childhood and treated with conventional therapy
36. Factors modifying the effect of hyperglycemia on the development of retinopathy in adolescents with diabetes. Results of the Berlin Retinopathy Study
37. Parental history of diabetes in a population-based study
38. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial
39. Genetic markers in early diabetic retinopathy of adolescents with type 1 diabetes
40. HLA-markers and diabetic retinopathy in the Senegalese population
41. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM
42. An aldose reductase intragenic polymorphism associated with diabetic retinopathy
43. Norman MacAllister Gregg Lecture. The pathogenesis of diabetic retinopathy
44. Contrasting fibrinolytic responses in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes
45. Increased von Willebrand-antihaemophilic factor A in diabetic retinopathy
46. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria
47. Endothelium-dependent vascular responses: Mediator and mechanism
48. Haemostatic variables associated with diabetes and its complications
49. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy
50. Coagulation activation in diabetes mellitus: The role of hyperglycemia and therapeutic prospects
51. Mechanism on disorders of coagulation and fibrinolysis in diabetes
52. Coagulation pathways and diabetic retinopathy: Abnormal modulation in a selected group of insulin-dependent diabetic patients
53. Elevation of plasma thrombomodulin level in diabetic patients with early nephropathy
54. Erythrocyte sodium-lithium countertransport and proliferative diabetic retinopathy
55. The vascular endothelium as a regulator of the ocular circulation: A new concept in ophthalmology?
56. Diabetes-induced vascular dysfunction in the retina: Role of endothelins
57. Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage
58. Circulating antipericyte auto-antibodies in diabetic retinopathy
59. Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus
60. Lupus anticoagulant positivity in insulin dependent diabetic patients: An additional risk factor in the pathogenesis of diabetic retinopathy?
61. Cells of the immune system and their cytokines in epiretinal membranes and in the vitreous of patients with proliferative diabetic retinopathy
62. Activated T lymphocytes in epiretinal membranes from eyes of patients with proliferative diabetic retinopathy
63. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22
64. The association of hyperlipidemia with retinopathy in diabetic patients aged 15-50 years in the county of Umea
65. Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration?
66. Lp(a) is not related to retinopathy in diabetic subjects
67. Lipids and lipoproteins in diabetic adolescents and young adults with retinopathy
68. Risk factors relevant to severity of diabetic retinopathy
69. Contributing factors to the pathogenesis of diabetic macular edema
70. Diabetic vitreopathy
71. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy
72. Increased expression of placental growth factor in proliferative diabetic retinopathy
73. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy
74. Severe diabetic retinopathy after cataract surgery
75. Acqueous vascular endothelial growth factor correlates with clinical outcome in diabetic cataract extraction
76. Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy?
77. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy
78. Expression of cytokines of epiretinal membrane in diabetic macular edema
79. Elevation of vitreous leptin in diabetic retinopathy and retinal detachment
80. Intravitreal growth factors in proliferative diabetic retinopathy: Correlation with neovascular activity and glycaemic management
81. Elevated levels of matrix metalloproteinases (MMPs) 2, 9 and tissue inhibitors of metalloproteinases (TIMPs) -1, -4 in the vitreous humour of diabetic patients
82. Matrix metalloproteinase biology applied to vitreoretinal disorders
83. Both vascular endothelial growth factor (VEGF) and hypoxia increase gelatinase (MMP-2) activity in vascular endothelial cells in vitro
84. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy
85. Micro-aneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group
86. Fluorescein aniography in children and adolescents with type 1 diabetes mellitus
87. Color photography vs fluorescein angiography in the detection of diabetic retinopathy in the Diabetes Control and Complications Trial
88. Visual fields at different stages of diabetic retinopathy
89. Blue-on-yellow and achromatic perimetry in diabetic children without retinopathy
90. Entoptic perimetry screening for central diabetic scotomas and macular edema
91. Ocular haemodynamics and colour contrast sensitivity in patients with type 1 diabetes
92. Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study report no. 15
93. Visual evoked potentials after photostress in newly diagnosed insulin dependent diabetic patients
94. Multifocal oscillatory potentials in type 1 diabetes without retinopathy
95. The influence of early diabetes on patterns electroretinogram
96. Relation between iridopathy and retinopathy in diabetes
97. Iris fluorescein angiography in clinical practice
98. Colour slides or digital photography in diabetes screening - A comparison
99. Is acetazolamide effective in the treatment of diabetic macular edema? A pilot study
100. Quantitative evaluation of macular thickness in normal and diabetic patients using optical coherence tomography
101. Objective monitoring of diabetic macular edema
102. Clinical validity and reproducibility of Retinal Thickness Analyzer (RTA) thickness measurements in patients with diabetic macular edema
103. Telemedicine and ophthalmology
104. Teleophthalmology: The use of real-time telementoring to remove an orbital tumor
105. Telemedicine screening of glaucoma
106. Evaluation of stereoscopic digital imaging to identify diabetic retinopathy via teleophthalmology
107. Barriers to prevention of vision loss caused by diabetic retinopathy
108. A modification of the Airlie House classification of diabetic retinopathy
109. Grading diabetic retinopathy from stereoscopic color fundus photographs-an exyension of the modified Airlie House classification. ETDRS report number 10
110. An alternative method of grading diabetic retinopathy
111. A quantitative system to evaluate diabetic retinopathy from fundus photographs
112. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11
113. Discordant diabetic retinopathy in homozygous twins: The importance of good metabolic control
114. The influence of combined kidney-pancreas transplantation on the progression of diabetic retinopathy. A case series
115. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial
116. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial
117. Retinopathy and Nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
118. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial
119. Randomised placebo-controlled trial of human recombinant insulin-like growth factor 1 plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus
120. A randomized trial of Sorbinil, an aldose reductase inhibitor, in diabetic retinopathy
121. The Astemizole Retinopathy Trial: Effect of astemizole on diabetic macular edema
122. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes
123. Treatment of nonproliferative diabetic retinopathy with defibrotide in noninsulin-dependent diabetes mellitus: A pilot study
124. Growth hormone replacement therapy is not associated with retinal changes
125. Early photocoagulation in patients with either type I or type II diabetes
126. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other characteristics at baseline: ETDRS report no. 19
127. One-year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy
128. The National Diabetic Retinopathy Laser Treatment Audit. III. Clinical outcomes
129. Report no. 5: Early vitrectomy for severe vitreous haemorrhage in diabetic retinopathy. Four-year results of a randomized trial
130. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report no. 17. Early Treatment Diabetic Retinopathy Study Research Group
131. Vitrectomy in the management of diabetic eye disease
132. Pathogenetic mechanisms in anterior proliferative vitreoretinopathy
133. Combined pars plana vitrectomy, lensectomy and silicon oil retinal tamponade in the initial management of complex retinal detachment associated with proliferative diabetic retinopathy
134. Long-term follow up after vitreous surgery in cases with diabetic neovascular glaucoma
135. Complications and prognosis of children with IDDM
136. Early diabetes-related complications in children and adolescents with type 1 diabetes. Implications for screening and intervention
137. Genetic heterogenity of autoimmune diabetes: Age of presentation in adults is influenced by HLA-DRB1 and DQB1 genotypes (UKPDS 43)